ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1153

Rheumatoid Arthritis Synovial Fibroblasts Lack Tolerization Of Inflammatory Cytokines and Matrix Degrading Enzymes After Repeated LPS Stimulation

Kerstin Klein1, Renate E. Gay2, Christoph Kolling3, Adrian Ciurea4, Beat A. Michel5, Lih-Ling Lin6, Steffen Gay1 and Caroline Ospelt1, 1Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, 2Center of Experimental Rheumatology, Zurich University Hospital, Zurich, Switzerland, 3Schultess Clinic, Zurich, Switzerland, 4Center of Experimental Rheumatology, University Hospital Zurich, Zurich Schlieren, Switzerland, 5Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 6Inflammation and Remodeling Research Unit, Pfizer, Cambridge, MA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Fibroblasts, tolerance and toll-like receptors

  • Tweet
  • Email
  • Print
Session Information

Title: Innate Immunity and Rheumatic Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose:

In macrophages, repeated stimulation of Toll-like receptor (TLR) 4 leads to adaptation of signaling pathways and epigenetic modifications resulting in a tolerant state of the cell and protecting inflamed tissues from inflammation-induced damage. We hypothesized that a lack of tolerization in rheumatoid arthritis synovial fibroblasts (RASF) significantly contributes to sustained inflammation and inflammation-induced damage seen in RA.

 The objective was to investigate tolerizable and non-tolerizable effects in RASF compared to macrophages.

Methods:

RASF and in vitro differentiated peripheral blood derived macrophages from healthy donors and RA patients were treated with LPS (100 ng/ml). 24h after the initial stimulation, cells were re-stimulated with LPS (10 ng/ml) for another 24h. Supernatants were collected from the second treatment period for ELISA and cells were harvested for isolation of RNA or protein extracts after a total treatment period of 48h. The expression of different genes, including cytokines and chemokines (IL6, CCL5, IL33, CXCL10), matrix metalloproteinases (MMP1, MMP3, MMP13), receptors (TLR2, TLR3, TLR4, MDA5, RIG1) as well as signaling molecules, activators and inhibitors of the TLR pathway (SHIP1, SOCS1, TNFAIP3, OAS1) was analyzed by quantitative Real-time PCR, Western blotting and ELISA. Nuclear factor-қB (NF-қB) and activator protein-1 (AP-1) promoter activities in RASF were evaluated by Dual-Luciferase reporter assays after repeated stimulation with LPS (100 ng/ml, 10 ng/ml).

Results:

As expected, the expression of IL6 decreased in double-stimulated (886 ± 596 pg/ml) compared to single-stimulated (2368 ± 315 pg/ml; p<0.01) macrophages from healthy donors (n=4) and RA patients (n=6, p=0.06). On the other hand, RASF (n=10) maintained their production of IL6 after repeated TLR4 stimulation and secreted 13237 ± 5764 pg/ml IL6 after a single LPS stimulation and 12421 ± 7178 pg/ml IL6 after double stimulation. A lack of tolerizable effects after LPS stimulation of RASF was also found for MMP1, MMP3, MMP13, CCL5, IL33, TLR3 and TNFAIP3. Interestingly, the known interferon-responsive genes OAS1, RIG1, MDA5 and CXCL10 were tolerizable not only in macrophages but also in RASF. RASF (n=5) secreted 531 ± 385 pg/ml CXCL10 after a single LPS stimulation and 111 ± 97 pg/ml CXCL10 after double stimulation (p<0.05). TLR4 mRNA was not changed in macrophages or in RASF by LPS double stimulation suggesting that a change of TLR4 expression itself was not responsible for tolerization. Reporter gene activities for NF-қB and AP-1 were similar in single and double stimulated RASF, excluding changes in signaling molecules as the underlying mechanism for tolerizable/non-tolerizable effects.

Conclusion:

Based on the fact that neither TLR4 expression nor signalling pathways are altered by repeated LPS stimulation, epigenetic modifications on target gene promoters are likely to contribute to differences in tolerization between RASF and macrophages. Since many pro-inflammatory cytokines and MMPs are non-tolerizable genes in RASF, we conclude that the lack of tolerization in these cells keeps them aggressive in persistent inflammation.


Disclosure:

K. Klein,
None;

R. E. Gay,
None;

C. Kolling,
None;

A. Ciurea,
None;

B. A. Michel,
None;

L. L. Lin,

Employment,

3;

S. Gay,
None;

C. Ospelt,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rheumatoid-arthritis-synovial-fibroblasts-lack-tolerization-of-inflammatory-cytokines-and-matrix-degrading-enzymes-after-repeated-lps-stimulation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology